Mild cognitive impairment (MCI) is a condition in which a person has problems with memory, language, executive function and visuospatial skills that are noticeable to others and can be observed in neuropsychological tests, but are not severe enough to interfere with everyday activities. MCI can further develop into dementia, retain its status, or sometimes revert to the normal cognitive status. A significant proportion of people with MCI later develop Alzheimer’s disease (AD).

This report provides the current prevalent population for Crohn’s disease across 14 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, the two types of MCI (amnestic and non-amnestic), as well as ApoE genotypes in MCI patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global MCI market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of MCI and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific ApoE genotypes on MCI prevalent population.
  • Identify sub-populations within MCI which require treatment.
  • Gain an understanding of the specific markets that have the largest number of MCI patients.